Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151288 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
A Phase 1 study, sponsored by Vaxcyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,015
- Enrollment target
NCT06151288: Completed Phase 1 study, sponsored by Vaxcyte.
NCT06151288 is a Phase 1 study that has completed, run by Vaxcyte. The registered enrollment target is 1,015 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1592% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151288, a Phase 1 study, has completed, sponsored by Vaxcyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.
Primary Outcome
Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group.
Interventions
- BIOLOGICAL 31 valent pneumococcal conjugate vaccine
- BIOLOGICAL 20 valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 1 |
What the finished NCT06151288 record still lists
NCT06151288 is an interventional study that assigns participants to a tested intervention. Its 1,015 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1592% higher).
The record links to 0 conditions, and to 2 interventions - of which 31 valent pneumococcal conjugate vaccine is the first listed.
NCT06151288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06151288 about?
NCT06151288 is a clinical study titled "Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults". The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection ...
What is the current status of trial NCT06151288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,015 participants. The study started on 2023-11-08. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT06151288?
The interventions under investigation include: 31 valent pneumococcal conjugate vaccine (BIOLOGICAL), 20 valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06151288?
This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06151288's enrollment target sits among peer trials
1,015 6th of 2000 higher than 1,995 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI